scholarly journals Research on Anal Squamous Cell Carcinoma

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 42
Author(s):  
Krishan R. Jethwa ◽  
Christopher L. Hallemeier

Anal canal and peri-anal squamous cell carcinomas (ASCCs) are relatively rare cancers that affect approximately 8000 patients per year in the United States [...]

2008 ◽  
Vol 15 (7) ◽  
pp. 1948-1958 ◽  
Author(s):  
Karl Y. Bilimoria ◽  
David J. Bentrem ◽  
Clifford Y. Ko ◽  
Andrew K. Stewart ◽  
David P. Winchester ◽  
...  

2020 ◽  
Vol 52 (01) ◽  
pp. 25-28

Kim J, Park MK, Li WQ et al. Association of vitamin A intake with cutaneous squamous cell carcinoma risk in the United States. JAMA Dermatol 2019; doi:10.1001/jamadermatol. 2019.1937


2019 ◽  
Vol 42 (7) ◽  
pp. 596-601 ◽  
Author(s):  
Aleksandr R. Bukatko ◽  
Parth B. Patel ◽  
Vindhya Kakarla ◽  
Matthew C. Simpson ◽  
Eric Adjei Boakye ◽  
...  

2020 ◽  
Vol 21 (4) ◽  
pp. 1211
Author(s):  
Elisabetta Palazzo ◽  
Maria I. Morasso ◽  
Carlo Pincelli

Cutaneous squamous cell carcinoma (cSCC) represents the second most frequent skin cancer, recently showing a rapid increase in incidence worldwide, with around >1 million cases/year in the United States and 2500 deaths [...]


2020 ◽  
Vol 27 (3) ◽  
Author(s):  
L. Cattelan ◽  
F. M. Ghazawi ◽  
M. Le ◽  
E. Savin ◽  
A. Zubarev ◽  
...  

Background Anal cancer is a rare disease, constituting 0.5% of new cancer cases in the United States. The most common subtype is squamous cell carcinoma (scc). Studies in several developed nations have reported on an increasing incidence of anal cancer in recent decades, and various risk factors pertaining to the pathogenesis of the disease have been identified, including infection with the human papillomavirus, tobacco use, and immunosuppression. The epidemiology and distribution of anal scc throughout Canada remain poorly understood, however. Methods Using 3 population-based cancer registries, a retrospective analysis of demographic data across Canada for 1992–2010 was performed. The incidence and mortality for anal scc was examined at the levels of provinces, cities, and the forward  sortation area (FSA) component (first 3 characters) of postal codes. Results During 1992–2010, 3720 individuals were diagnosed with anal scc in Canada; 64% were women. The overall national incidence rate was 6.3 cases per million population per year, with an average age at diagnosis of 60.4 years. The incidence increased over time, with significantly higher incidence rates documented in British Columbia and Nova Scotia (9.3 cases per million population each). Closer examination revealed clustering of cases in various urban centres and self-identified lgbtq communities in Toronto, Montreal, and Vancouver. Discussion This study provides, for the first time, a comprehensive analysis of the burden of anal scc in Canada, identifying susceptible populations and shedding light onto novel avenues of research to lower the incidence of anal cancer throughout the country.


2019 ◽  
Vol 22 ◽  
pp. S65
Author(s):  
A. Berger ◽  
M. Contente ◽  
N. Kumar ◽  
P. Abraham ◽  
R. Shah ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17554-e17554
Author(s):  
Matthew Gaubatz ◽  
Aleksandr R Bukatko ◽  
Katherine M. Polednik ◽  
Matthew C Simpson ◽  
Eric Adjei Boakye ◽  
...  

e17554 Background: There has been a shift in the epidemiologic landscape of head and neck cancer (HNC) with decreasing incidence of tobacco-related and increasing incidence of human papillomavirus (HPV)-related HNC. While it is often reported that ≥ 90% of HNC is considered squamous cell carcinoma (SCC), there is an apparent lack of recent population-based data to support this claim. This study aimed to estimate the current proportion and evaluate change in the proportion of SCC in HNC diagnoses in North America (United States and Canada) from 1995 to 2015. Methods: We queried the North American Association of Central Cancer Registries (NAACCR) database for HNC cases that were of either squamous (SQ) (ICD-0-3: 8050-8089) or squamous plus unspecified epithelial (SQE) (ICD-0-3:8010-8089) origin in the United States and Canada ( n = 1,054,409). All HNC included in the analysis were microscopically confirmed, malignant head and neck primary tumor sites of the oral cavity, nasopharynx, hypopharynx, oropharynx, nasal cavity, and larynx. Sub-analyses were conducted across more extensive cohort restriction combinations (country specific, registry specific, and primary sequence of cancer). Results: The overall proportion of SCC in HNC in North America from 1995-2015 was 81.7% (95% CI: 81.7 – 81.8) for SQ and 84.9% (95% CI: 84.8 – 85.0) for SQE. The proportion of SCC in HNC peaked in 2015 with 83.3% (95% CI: 83.0 – 83.6) for SQ and 85.9% (95% CI: 85.6 – 86.2) for SQE; and was lowest in 2005 with 80.7% (95% CI: 80.4 – 81.1) for SQ and 84.3% (95% CI: 83.9 – 84.6) for SQE. In the time period of this study (1995 – 2015), there were no years for which SQ or SQE made up 90% or more of HNC for any of the HNC cohorts. Conclusions: The changing landscape of HNC risk factors in the United States and Canada warrants re-evaluation and update of HNC epidemiological literature with regards to the proportion of SCC in HNC.


Sign in / Sign up

Export Citation Format

Share Document